Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 11/20 | 0.54 |
| ▸ | METAP2 | P50579 | 4/20 | 0.47 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793804 | 1.00 | IDO1 (0.54) | IDO1METAP2TDO2NR3C1MET | |
| SCHEMBL25081099 | 0.86 | IDO1 (0.56) | IDO1METAP2TDO2NR3C1 | |
| SCHEMBL29793832 | 0.81 | METAP2 (0.46) | IDO1METAP2TDO2MET | |
| SCHEMBL20509236 | 0.81 | METAP2 (0.46) | IDO1METAP2TDO2MET | |
| Hydrochloric Acid SCHEMBL31308499 | 0.76 | METAP2 (0.49) | IDO1METAP2TDO2 | |
| SCHEMBL30861084 | 0.74 | IDO1 (0.61) | IDO1METAP2TDO2CHEK1 | |
| SCHEMBL304051 | 0.74 | IDO1 (0.61) | IDO1METAP2TDO2CHEK1 | |
| SCHEMBL22079091 | 0.74 | IDO1 (0.53) | IDO1METAP2MET | |
| SCHEMBL28592498 | 0.74 | IDO1 (0.53) | IDO1METAP2MET | |
| SCHEMBL8404433 | 0.74 | IDO1 (0.63) | IDO1METAP2TDO2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| EP-3601267-A1 | 2-METHYL-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172250-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | IDO1 3292/4885METAP2 2289/4885TDO2 2636/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | IDO1 3292/4885METAP2 2289/4885TDO2 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.